AbbVie Inc. (SNSE:ABBVCL)

Market Cap	356.82T +11.8%
Revenue (ttm)	55.09T +8.6%
Net Income	3.81T -1.2%
EPS	2,125.82 -1.3%
Shares Out	n/a
PE Ratio	93.73
Forward PE	15.96
Dividend	6,282.40 (3.66%)
Ex-Dividend Date	Jan 16, 2026

Volume	n/a
Average Volume	n/a
Open	n/a
Previous Close	171,590
Day's Range	n/a
52-Week Range	160,521 - 219,480
Beta	n/a
RSI	29.67
Earnings Date	Feb 4, 2026

About AbbVie

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2012
• Employees: 55,000
• Stock Exchange: Santiago Stock Exchange
• Ticker Symbol: ABBVCL

Financial Performance

In 2025, AbbVie's revenue was $61.16 billion, an increase of 8.57% compared to the previous year's $56.33 billion. Earnings were $4.23 billion, a decrease of -0.28%.

Financial numbers in USD